On October 28, 2024, David Campbell, President and Chief Executive Officer of Janux Therapeutics Inc (JANX, Financial), executed a sale of 25,000 shares of the company. The transaction was filed on October 30, 2024, as reported in the SEC Filing. Following this sale, the insider now owns 282,054 shares of Janux Therapeutics Inc.
Janux Therapeutics Inc is engaged in the development of cancer treatments. The company focuses on creating therapies that harness the body's immune system to combat and eradicate cancer effectively.
Over the past year, the insider has sold a total of 50,000 shares and has not made any purchases. The recent transaction reflects a continuation of this selling trend among insiders at Janux Therapeutics Inc, which has seen 12 insider sells and 4 insider buys over the past year.
Shares of Janux Therapeutics Inc were trading at $53.54 on the day of the sale. The company currently holds a market cap of approximately $2.921 billion.
According to the GF Value, the intrinsic value of Janux Therapeutics Inc is estimated at $25.30 per share, making the stock significantly overvalued with a price-to-GF-Value ratio of 2.12. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This insider sale may interest investors tracking insider behaviors as an indicator of the company's future performance and valuation alignment.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
